This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Momenta Pharmaceuticals' CEO Presents At Goldman Sachs 33rd Annual Global Healthcare Conference (Transcript)

Momenta Pharmaceuticals, Inc. (MNTA)

Goldman Sachs 33rd Annual Global Healthcare Conference

June 7, 2012 12:20 p.m. ET


Craig Wheeler - CEO


Sapna Srivastava - Goldman Sachs


Sapna Srivastava - Goldman Sachs

Thank you. Good morning and thanks for joining us. I am Sapna Srivastava, biotech analyst at Goldman Sachs. And it’s my pleasure to host Craig Wheeler, CEO of Momenta. And thank you so much Craig for coming, really appreciate to know with the trip (indiscernible) with the morning here.

Before we go into the discussion, I just want to read this out to the audience. We’re required to make certain disclosures and public appearances about Goldman Sachs’ relationships with companies that we discuss. The disclosures relate to investment banking relationships’ compensation received or 1% or more ownership. I am prepared to read disclosures if anyone would like me to, however, these disclosures are available in our most recent reports available to U.S. clients on our firm’s portals. Views of non-Goldman Sachs personnel may not represent the company views.

And with that, I will kick it off, and just a reminder to the audience we would like this to be interactive. So please ask as many questions as you have. Craig, when we sat down here last year, it’s amazing to me how much has happened at Momenta since then, from the Lovenox side of it to the Baxter side of it. I would just love to get your views over like, this really I think a period of massive activity and evolution of the company, where do you see your most – your largest key opportunities now and where you are most focused for taking the company towards?

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,712.66 +34.43 0.19%
S&P 500 2,061.02 +4.87 0.24%
NASDAQ 4,891.2190 +27.8570 0.57%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs